The role of small leucine-rich proteoglycans in osteoarthritis pathogenesis  by Ni, G.-X. et al.
Osteoarthritis and Cartilage 22 (2014) 896e903ReviewThe role of small leucine-rich proteoglycans in osteoarthritis
pathogenesis
G.-X. Ni y*, Z. Li y, Y.-Z. Zhou z
yDepartment of Orthopeadics and Traumatology, Nanfang Hospital, Southern Medical University, China
zDepartment of Rehabilitation Medicine, 1st Afﬁliated Hospital, Fujian Medical University, Chinaa r t i c l e i n f o
Article history:
Received 26 January 2014
Accepted 23 April 2014
Keywords:
Small leucine-rich repeat proteoglycans
Osteoarthritis
Pathogenesis* Address correspondence and reprint requests
Orthopeadics and Traumatology, Nanfang Hospital,
Guangzhou 510515, China. Tel: 86-20-61641744; Fax:
E-mail addresses: fgxni@graduate.hku.hk, nigx69@
http://dx.doi.org/10.1016/j.joca.2014.04.026
1063-4584/ 2014 Osteoarthritis Research Society Ins u m m a r y
Objective: To give an overview of the literature on the role of small leucine-rich proteoglycans (SLRPs) in
osteoarthritis (OA) pathogenesis.
Method: A literature search was performed and reviewed using the narrative approach.
Results: (1) OA is an organ disease with many tissue types and speciﬁc roles for each in the pathogenic
process. (2) Key biological functions of SLRPs include interacting with collagens to modulate ﬁbril for-
mation, and binding various cell surface receptors and growth factors to inﬂuence cellular functions; (3)
Accumulating evidence has demonstrated the involvement of SLRPs in OA pathogenesis, most of which
came from SLRP-deﬁcient mice models; (4) Possible mechanisms for SLRPs being involved in OA path-
ogenic process include their roles in the extracellular collagen network, TGF-b signaling pathways,
subchondral bone, muscle weakness, and the innate immune inﬂammation; (5) SLRP-deﬁcient mice offer
a potential to understand the molecular mechanisms of OA initiation and progression. (6) Targeting
SLRPs may offer a new therapeutic modality for OA through controlling and modifying the TGF-beECM
system. (7) Monitoring SLRP fragmentation may be a promising biomarker strategy to evaluate OA status.
Conclusions: Recent literature has shown that SLRPs may play an important role in OA pathogenesis.
Possible mechanisms by which SLRPs are involved in this process have also been proposed. However,
further investigations are needed in this ﬁeld to better understand its mechanisms, develop treatments
to slow down the degenerative process, and explore new approaches for effective and timely diagnosis
of OA.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is themost common joint disease in humans,
affecting about 10% of the world population over 60 years of age1. It
causes pain and disability, and is associated with substantial eco-
nomic burden and serious socioeconomic consequences2. OA is a
polygenic disease controlled by genetic and environmental factors,
but its precise etiology is unclear. Althoughmainly characterized by
the degradation of articular cartilage, it is best considered as a dis-
ease of the whole “joint organ”3. Evidence regarding functional as-
pects of the susceptible genes supports the view that all tissues
within the joint may contribute to OA4. As for cartilage, injury,
excessivewear and tear through overuse, aswell as age, are stronglyto: G.-X. Ni, Department of
Southern Medical University,
86-20-62787924.
163.com (G.-X. Ni).
ternational. Published by Elsevier Lassociated with the development of OA. It is also recognized that
intra-articular derangement such as ligament transaction or
meniscectomy is a risk factor for the onset and progression of OA.
Moreover, OA is closely linked to the changes in the periarticular
structures, such as skeletal muscle, tendon, and bone.
Epidemiological studies demonstrated that genetic factors are
strong determinants of OA, and a few predisposing genes have been
identiﬁed5,6. As a group of biologically active components of the
extracellular matrix (ECM) of all tissues, small leucine-rich pro-
teoglycans (SLRPs) have important effects on cell behavior, thus
having implication in many biological functions7. Previous studies
have revealed widespread involvement of SLRP genes in various
pathogenic mechanisms causing skin fragility, osteoporosis, oste-
osarcoma, cardiovascular disease, and so on8e10. During the past
one or two decades, evidence is surfacing for involvement of SLRPs
in the pathogenesis of OA8,11. The following review will summarize
the up-to-date knowledge about the role of SLRPs in OA patho-
genesis, and propose several mechanisms as to how SLRPs can be
involved in this process.td. All rights reserved.
Table I
Classiﬁcation, general structural characteristics, and distribution of SLRPs
SLRP (gene) Protein
core* (kDa)
GAGy
(type)
Abundant in
joint tissue
Class I
Biglycan (BGN, PGS1) 38 CS/DS Tendon, bone,
cartilage, muscle
Decorin (DCN, PGS2) 36 CS/DS Tendon, cartilage,
muscle
Asporin (ASPN) 42 Periosteum
ECM2 77
Uncharacterized new small leucine-rich
proteoglycan on the human
X chromosome (ECMX)
64
Class II
Fibromodulin (FMOD) 42 KS Tendon, ligament,
cartilage
Lumican (LUM) 38 KS Cartilage, bone
PRELP 44 KS Cartilage
Keratocan (KERA) 38 KS Tendon, ligament,
cartilage
Osteoadherin (OSAD) 42 KS Bone
Class III
Epiphycan (EPYC, PG-Lb, DSPG-3) 36 CS/DS Cartilage, bone
Opticin (OPT) 35e45 Cartilage
Osteoglycin (OGN), mimecan (MIME),
osteoinductive factor (OIF)
35 KS
Class IV
Chondroadherin (CHAD) 36 KS Cartilage
Nyctalopin 50
Tsukushi (TSK) 40
Class V
Podocan (PODN) 70
Podocan like protein-1 (PODNL1) 57
* The approximate molecular weight of protein core (kDa) without post-
translational modiﬁcations.
y The type of GAG provided only by classical PGs (CS/DS: chondroitin sulfate/
dermatan sulfate, KS: keratan sulfate).
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Proteoglycans (PGs) are widely distributed in all connective tis-
sues and formed of glycosaminoglycans (GAGs) covalently attached
to the core proteins. They have been classiﬁed into ﬁve families ac-
cording to the structural properties of their core proteins12. One of
such families is SLRPs, whichwere originally grouped on the basis of
their relatively small protein core (36e42 kDa) in comparison with
the larger aggregating PGs such as aggrecan andversican (more than
200 kDa), and on their unique structural organization composed of
tandem leucine-rich repeats (LRRs)7,12. SLRPs can be generally
described as two-part constructs. One part is N-terminal variable
domain, and the other the conserved domain of LRRs [Fig. 1]. It was
revealed that SLRPs are nonglobular, horseshoe-shaped, and
solenoid-like molecules by molecular modeling and electron mi-
croscopy13. The horseshoe concave surface is formed by the LRR’s b-
sheets, whereas the LRR’s a-helices and the SLRP’s diverse carbo-
hydrate moieties ﬂank the convex surface13. Such structure is well
suited for proteineprotein interactions.
The rapidly growing SLRP family currently comprises 18
members, which are grouped into ﬁve distinct classes, including
the traditionally deﬁned classes IeIII, and the non-canonical
classes IV and V (Table I), based on such parameters as N-termi-
nal Cys-rich clusters of the protein core and ear repeats, evolu-
tionary conservation and homology at both the protein and
genomic level, and chromosomal organization14,15. Regardless of
the classiﬁcation used, however, some SLRPs share common
functionality8. Besides, diversity in composition enables SLRPs to
facilitate proteineprotein interactions with different cell and ma-
trix components.
Key biological roles of SLRPs
When the ﬁrst two SLRPs were cloned and sequenced about 25
years ago, they were only considered as one component of PGs16.
Currently, it is well recognized that the SLRPs can be implicated in
many biological functions, which have been extensivelyFig. 1. Schematic presentation of the SLRP family members’ molecular structure. The
core protein of decorin, biglycan, Fmod or LUM is depicted with two disulphide
bonded domains ﬂanking ten LRR domains. In the case of decorin or biglycan, one or
two CS/DS chains, respectively, reside in the amino terminal region. In the case of
Fmod and LUM, one to four keratin sulphate chains (KS) may reside between the LRR
domains (modiﬁed from Glycoword, www.gak.co.jp).reviewed14,17e19. However, little is known about the involvement of
SLRPs in OA pathogenesis.
The unique structure of SLRPs enables them to interact with a
variety of other proteins14. Through interacting with collagens,
they can modulate ﬁbril formation18 with convincing evidence
from disorganized collagen ﬁbrils in the SLRPs-deﬁcient mice
that consequently lose some connective tissue functions.
Changes in the extracellular collagen network may cause the
joint structures less suited to withstand physiologic mechanical
loading, contributing to the development of OA. It is also spec-
ulated that different SLRPs may contain proteins for different
stages of collagen ﬁbrillogenesis20,21. Many SLRPs are therefore
required for this process. In addition, regulation of collagen
ﬁbrillogenesis may not only be controlled by the expressions, but
also by collagen-binding competition within the SLRPs. It is
suggested that the SLRPs interact with collagen through speciﬁc
binding sites18. Furthermore, various SLRPs may interact with
collagen ﬁbrils to form a “surface coat” as a steric barrier limiting
the access of the collagenases to their cleavage site, and to
regulate the physiology of collagenous matrices in a tissue-
speciﬁc manner22.
Another key role of SLRPs is that they are able to bind various
cell surface receptors, growth factors, cytokines and other ECM
components resulting in the ability to inﬂuence various cellular
functions14. Through binding to extracellular components such as
their ligands and receptors, SLRPs can directly regulate ligand-
induced signaling pathways. Among them, the major targets of
SLRPs are members of the transforming growth factor (TGF)-b su-
perfamily pathways, including the bone morphogenetic protein
(BMP) pathway23,24. Many recent studies have shown that SLRP
members have the ability to regulate more than one signaling
Table II
OA-related phenotypes in KO mice
Ref SLRP Tissue(s)
assessed
Phenotype
50 BGN
Fmod
BGN/Fmod
Knee tendon,
cartilage
Collagen ﬁbrils in tendons from mice
deﬁcient in BGN and/or Fmod are
structurally and mechanically altered,
resulting in unstable joints, tendon
ossiﬁcation and OA
51 LUM/Fmod Knee tendon The LUM/Fmod deﬁcient mice displayed
gait abnormality, joint laxity, and OA.
Fmod acted as a key regulator and LUM
as a modulator of tendon strength
52 Fmod Knee cruciate
ligaments
Cartilage degeneration in Fmod-deﬁcient
mice could be secondary to defects in the
ligaments stabilizing the knee joint with
no abnormalities in ECM of articular
cartilage
53 EPN
EPN/BGN
Knee cartilage EPN plays an important role in maintaining
joint integrity. The severity of OA
phenotype in the EPN/BGN double-deﬁcient
mouse
suggests a synergy between EPN and BGN
54 BGN
Fmod
BGN/Fmod
Knee ligament,
tendon, menisci
At 3 months, all mutant mice displayed torn
cruciate ligaments and EO in the targeted
tissues. The phenotype was the least severe
in the Fmod KO, intermediate in the BGN
KO and the most severe in the DKO
55 BGN/Fmod TMJ cartilage Increased apoptosis of chondrocytes
induced by the BGN and Fmod deﬁciency
resulting in the early development of
TMJ OA
56 BGN/Fmod TMJ cartilage Impairment in chondrocyte proliferation
induced by the BGN and Fmod deﬁciency
resulting in the early development of
TMJ OA
57 BGN/Fmod TMJ cartilage The absence of BGN and Fmod disrupted
the balance between ECM formation and
degradation to the development of
TMJ OA
DKO, double knockout.
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ation, migration, and phenotype25,26. It is also demonstrated that
some SLRPs are essential in regulating cell biology, differentiation
and migration behavior of mesenchymal stem cell-derived pro-
genitor cells27e29, which play important roles in OA pathogen-
esis30,31. What is more, SLRPs can be involved in activation of
complement system32 and Toll-like receptor (TLR) pathways33,
thereby having implications in chronic inﬂammatory processes and
OA pathogenesis.
The involvement of SLRPs in OA pathogenesis
A large number of SLRPs are expressed in cartilage, including
biglycan (BGN), chondroadherin (CHAD), decorin, epiphyean (EPN),
ﬁbromodulin (Fmod), keratocan, lumican (LUM), opticin (OPT), and
proline/arginine-rich end leucine-rich repeat protein (PRELP)34e36.
Additionally, the increased fragmentation of many SLRPs (BGN,
decorin, Fmod, keratocan, and LUM) has been extensively reported
in articular cartilage from age-matched OA joints compared with
nonarthritic joints37,38. Many other studies demonstrated that
chondrocytes increased the production of the SLRPs as an attempt
to repair damaged ECM37,39. As such, it is suggested that the SLRP
family members may be crucial to maintain normal chondrocyte
activity and cartilage tissue integrity, and alterations in the distri-
bution and production of SLRPs could lead to the development of
OA34,35.
Asporin (ASPN), a class I SLRP, was discovered in 2001 by Lor-
enzo et al.34 and Henry et al.40. It was named based on the presence
of a unique stretch of aspartate residues at its N terminus and the
similarity with decorin34. However, unlike decorin and BGN, ASPN
does not contain GAG chains. Its expression in cartilage of in-
dividuals with knee OA was greater than that of unaffected in-
dividuals40. Further in vitro evidence shows that ASPN acts as a
negative regulator of chondrogenesis by inhibiting TGF-b func-
tion41. An association between the D-repeat polymorphism and
Knee OA (KOA) susceptibility was ever demonstrated in the Han
Chinese42 and Japanese populations41. However, published results
have been inconsistent. Positive association was not demonstrated
in studies in Caucasians43e45. What is more, although strong as-
sociation between D-repeat and knee OA in Asians was found in a
meta-analysis46, a subsequent study in Korean populations re-
ported no difference in the frequency of the different ASPN alleles
between the knee OA patients and the healthy controls47. It is due to
the inclusion of this study that negative results were found in the
two other recent meta-analyses48,49. More studies are required to
draw the exact conclusion in Asian populations.
Previously, a lot of key information regarding the function and
tissue expression pattern of SLRPs has been gathered from the
available knockout (KO) mice, which can represent valuable in vivo
models for various diseases8. Similarly, more and more in-
vestigations have used SLRP-deﬁcient mice models and provided
direct and valuable evidence for involvement of SLRPs in the
pathogenesis of OA (Table II).
As shown in Table II, a large number of single and double SLRPs-
deﬁcient mice developed an OA-like change, including BGN-,
Fmod-, and EPN-deﬁcient, as well as BGN/Fmod, LUM/Fmod, and
EPN/BGN double-deﬁcient, suggesting that SLRPs may play an
important role in maintaining joint integrity. The fact that many
double SLRP-deﬁcient mice display relatively severe phenotypes
compared with their single SLRP-deﬁcient counterparts50e53 in-
dicates that either these SLRPs have some overlapping functions
within cartilage, or each SLRP has independent functions that,
when deleted, exacerbate the progression of OA. Of note, although
the single KO may have some features of the double KO, their
mechanism of action could be different. For example, the absence ofBGN may reduce induction of BMP-2 (to induce osteogenesis)54,
whereas, depletion of BGN and Fmod may increase BMP-2 causing
osteogenesis in the tendon50,55. Interestingly, some SLRPs may
compensate for the loss of others. For instance, the mRNA levels of
three different SLRPs (ASPN, Fmod, and LUM) are increased in EPN/
BGN double-deﬁcient mice as compared with wild type mice53. A
signiﬁcant increase in LUM levels was found in cartilage, cruciate
ligaments52 and tendon51 in Fmod-null mice. More BGN was also
reported in decorin-deﬁcient tendons21, and more LUM in Fmod-
deﬁcient tendons56.
Distinct in vivo function for each SLRP has been summarized in
recent reviews8,18, reﬂected by the distinct phenotypes developed
by the different single deﬁcient mice. Moreover, although various
SLRPs are involved in OA development, their roles may be different
from one another. Ezura et al.20 showed mild and moderate alter-
ation in collagen ﬁbril structure of tendons in the LUM-null and
Fmod-null mice, respectively. In another study53, a progressive
degeneration of articular cartilage was found in either EPN- or
BGN-deﬁcient mice model, but the onset of OA was observed at 9
and 6 months, respectively. Kilts et al.55 also demonstrated that
BGN deﬁciency resulted in a signiﬁcantly more severe impairment
of the soft tissues by 3 months of age in comparison with Fmod
deﬁciency. Such differential impairment may arise from a func-
tional difference between various SLRPs or due to a difference in
SLRP composition between these tissues51,55. On the other hand,
SLRPs deﬁciency appears to have joint type-dependent effect on the
progression of OA. Mice deﬁcient in BGN and Fmod developed OA
in temporomandibular joint (TMJ) at 6 months, and by 18 months
of age, there was almost complete destruction of the TMJ joint57.
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OA ﬁrst appeared as early as 1e3 months, and by 6 months, there
was almost complete destruction of the knee joint50. Such differ-
ences may be due to the differences in the anatomy and structure of
the joints.
Possible mechanisms of SLRPs in OA pathogenesis
Although accumulating evidence demonstrates the involvement
of SLRPs in OA pathogenesis, its precise mechanism is still unclear.
The most striking pathologic change of OA is the progressive loss of
articular cartilage. However, OA is not a disease of only articular
cartilage, but involves all the tissues of the joint3. As SLRPs are
present within the ECM of all connective tissues, and play impor-
tant roles in the integrity of many musculoskeletal tissues,
including bone, cartilage, ligament, tendon, etc, their involvement
in the pathogenesis of OA may be through a single or combined
ways depending on the type of SLRPs. The involvement of SLRPs in
the development of OA may be associated with the following po-
tential mechanisms [Fig. 2].
Changes in the extracellular collagen network
Depletion of SLRPs causes changes in the extracellular collagen
network, making the joint structures less suited to withstand
physiologic mechanical loading. Collagen loss was found at artic-
ular cartilage surface in both BGN-deﬁcient and EPN/BGN double-
deﬁcient mice53. In addition, degenerative changes were detected
in the cruciate ligaments of mice deﬁcient in BGN55, Fmod52,55, and
BGN/Fmod55. In parallel, an excessive number of very small
collagen ﬁbrils were observed in tendons of mice deﬁcient in
Fmod51 and BGN/Fmod50 compared with age-matched wild type
mice. Importantly, these changes were present before OA started to
develop, suggesting that such changes in collagen network in
mutant animals may be responsible for increasing their suscepti-
bility to develop knee OA.Fig. 2. A mechanistic model depicting how absence of SLRPs leads to OA. Firstly, deplet
extracellular collagen network, and impairment in chondrocyte proliferation through modu
“surface coat” to limit the access of the collagenases to their cleavage sites. SLRP degradation
this macromolecule. Secondly, depletion of SLRPs may cause an excessive number of very sm
instability. In addition, EO is extensively detected in soft tissues, including meniscus, ligamen
Other possible mechanisms include altered subchondral bone structure and muscle dystrop
complement system and TLR pathways, thereby having implications in OA pathogenesis.Various SLRPs interact with collagen ﬁbrils to form a “surface
coat” to limit the access of the collagenases to their cleavage sites22.
Since cleavage of the SLRPs may precede major destruction of the
collagen, this would contribute to its interference with the network
stability, preventing its repair and accelerating its degradation58,59.
A number of matrix metalloproteases (MMPs) are able to cleave
SLRPs11. As MMP-13 was demonstrated to play a major role in
cartilage degradation, Monfort et al.59 investigated its ability to
cleave members of two classes of SLRPs: BGN and decorin, as well
as Fmod and LUM, and found extensive cleavage on Fmod and BGN.
This suggests that SLRP degradation induced by MMP-13 may
represent an early critical event in the process of cartilage degra-
dation, by exposing the collagen ﬁbrils to proteolytic attack and
permitting subsequent cartilage degeneration.
TGF-b signaling pathways
SLRPs may bind with and modulate members of TGF-b super-
family, which are necessary for integrity of cartilage, tendon and
ligament. TGF-b, a key regulator of chondrocyte differentiation and
proliferation, has an important role in the pathogenesis of OA60.
The binding of SLRPs to members of the TGF-b family may regulate
their activity by sequestering them into the ECM, thereby pre-
venting their binding with the cellular receptors. Nevertheless,
SLRP/growth factor interactions are quite complex, whether SLRP
help or hinder growth factors depends on the tissue context17. In
this context, whether TGF-b “bad” or “good” for joint health may
relate to the use of the SLRP models.
Prior to the onset of OA, decrease in chondrocyte number was
commonly observed in knee articular cartilage in BGN-deﬁcient
and EPN/BGN double-deﬁcient mice53, as well as in both knee
articular cartilage and TMJ ﬁbrocartilage in ﬁbromodulin/BGN
double-deﬁcient mice57,61. ASPN was also found to work as a
negative regulator in chondrocyte differentiation and cartilage ECM
formation through suppressing TGF-bemediated expression of the
genes aggrecan and type II collagen to reduce proteoglycan (PG)ion of SLRPs may cause cartilage destruction in many ways, such as changes in the
lating TGF-b activity. Additionally, various SLRPs interact with collagen ﬁbrils to form a
induced by MMP may affect the collagen network by exposing the MMP cleavage site in
all collagen ﬁbrils and degenerative changes in tendon and ligament, leading to joint
t and tendon, through regulating BMPs, which is correlated to the development of OA.
hy secondary to the depletion of SRLPs. Finally, SLRPs can be involved in activation of
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ation induced by SRLPs deﬁciency could be a key event in the early
development of OA. In the bone marrow stromal cells from BGN/
decorin double-deﬁcient mice, an increase in TGF-b activity was
reported by Bi et al.62. Embree and colleagues63 further demon-
strated that the sequestration of TGF-b1 was decreased within the
ECM of BGN/ﬁbromodulin deﬁcient mandibular condylar chon-
drocytes (MCCs), leading to overactive TGF-b1 signal transduction,
chondrogenesis and ECM turnover.
On the other hand, ectopic ossiﬁcation (EO) was extensively
detected in soft tissues, including meniscus, ligament and tendon,
in mice deﬁcient in BGN53,55, ﬁbromodulin55, BGN and ﬁbromo-
dulin50,55, as well as EPN and BGN53. The formation of EO can be
seen as a localized attempt to compensate for the original
decreased stiffness of tissues. Due to ECM “microdamage”, the
SLRP-deﬁcient tissues may respond to external forces by changing
their compositions. The fact that additionally forced use of the joint
increases EO and OA in the BGN/ﬁbromodulin double mutants
supports this mechanistic model50,55. It is proposed that BMPs are
involved in the formation of EO55,62. tendon stem/progenitor cells
(TSPCs) were found to reside within a unique niche predominantly
comprised of the ECM62. The normal ECM-rich niche controls the
BMP activity so that TSPC can differentiate into tenocytes that form
tendon. However, depletion of BGN and ﬁbromodulin can affect the
differentiation fate of TSPC by stimulating the BMP signaling
pathway62. Recently, Kilts et al.55 also proposed that tendons
depleted of BGN or ﬁbromodulin may fail to bind and regulate
BMPs, and this unregulated BMPs activity would lead to more
stimulation of TSPCs by BMPs causing them to form ectopic bone
instead of normal tendon.
Roles in subchondral bone
OA arises indirectly from the altered subchondral bone struc-
ture. The role of subchondral bone is currently believed to be of
particular importance in the pathogenesis of OA64. Although
convincing evidence is lacking to support this notion, there are
substantial data to show the important role of some SLRPs in bone
formation. For example, compared with wild-type mice, BGN-
deﬁcient mice displayed slow bone growth and reduced bone mass
due to a signiﬁcant decline in osteoblast number and progressive
depletion of the bone marrow stromal cells54. Chen et al.29 further
suggested that the development of age-related osteopenia in BGN-
deﬁcient mice may be attributed to a defect in the quantity and
quality of osteoblastic progenitors resulting from the altered
expression of sets of genes associated with cell cycle, cell growth,
and differentiation. It was also reported that male EPN-deﬁcient
mice had signiﬁcantly shorter femurs than wild type mice at 9
months53. In addition, the class II SLRP, PRELP, may impair osteo-
clastogenesis to prevent osteopenia65.
Muscle weakness
Muscles and joints are functionally interdependent, as muscles
stabilize joints and contribute signiﬁcantly to their loading. Muscle
weakness is an acknowledged associate of joint degeneration and
OA66. In a rabbit model67, botulinum toxin type-A induced quad-
riceps weakness was found to cause increased degeneration in the
retro-patellar cartilage, providing evidence that muscle weakness
might be a risk factor for the onset and progression of OA. Tonge
et al. further reported that disease initiation in the ageing guinea
pig model of OA is coincident with altered expression of mRNAs
associatedwith quadriceps skeletal muscle contractile properties68.
Therefore, another possible explanation is that OA arises indirectly
from the induced muscle dystrophy. A number of studies haveshown that BGN binds and regulates some components of DAPC
(dystrophin-associated protein complex) and may play a role in
muscular dystrophies69. A mild muscular dystrophic phenotype
was displayed in mice deﬁcient in BGN characterized bymembrane
disruption and cell death of a subpopulation of myoﬁbers70. As for
decorin, different roles were reported during skeletal muscle for-
mation and repair. This protein inhibits the expression of myoge-
nin, a muscle-speciﬁc transcription factor, which promotes
myoblasts differentiatio71. It was also reported to modulate myo-
blasts proliferation in vitro through binding myostatin72, a member
of the TGF-b family of growth factors. Decorin sequesters myostatin
in the ECM, thus favoring myogenic cell proliferation and
differentiation.
The innate immune inﬂammation
As a whole joint disorder, OA affects all joint tissues that
communicate at the cellular level by releasing and responding to
inﬂammatory mediators. Synovial inﬂammation is increasingly
recognized as an important pathophysiologic process in OA. The
complement system, a crucial part of the innate immune defense, is
found to be associated with the chronic inﬂammation in OA73.
Recently, a role of SLRPs has been proposed in the regulation of
complement activation in diseases involving the ECM, particularly
those characterized by chronic inﬂammation, like OA32. Fibromo-
dulin or LUM can directly bind to C1q and activate the classical
pathway of complement32,74. However, BGN, along with decorin,
can function as an anti-inﬂammatory protein by binding to and
blocking the complement protein C1q, thereby inhibiting activation
of the complement cascade and proinﬂammatory cytokine pro-
duction at the tissue level75.
Activation of TLR pathways may also play a central role in the
development and progression of OA76. A role has been suggested of
signaling molecules and crucial proinﬂammatory factors in some
SLRPs. For example, BGN acts in macrophages as an endogenous
ligand of TLR4 and TLR2, and stimulates the expression of tumor
necrosis factor alpha (TNF-a) and macrophage inﬂammatory
protein-2 (MIP-2) via activation of p38, ERK, and NF-kappaB33. LUM
is also involved in innate immune response by affecting TLR4
signaling pathway. LUM-deﬁcient macrophages show impaired
response to lipopolysaccharides resulting in lower induction of
TNF-a and interleukin-677. Although SLRPs have potentials as key
modulators of the OA microenvironment, additional studies need
to be performed to understand the relationships of the SLRPs with
complement system and TLRs, as well as their roles in the devel-
opment and progression of OA.
Conclusions and future directions
In this review, up-to-date information has been gathered to
analyze the involvement of many SLRPs in the development of OA.
It is well known that a large number of single or double SLRPs-
deﬁcient mice can develop an OA-like disease. Although OA is a
major cause of disability in the ageing population with an
increasing prevalence and inﬂuential social consequences1, funda-
mental treatment for OA is lacking. Current therapy for OA is largely
palliative, mainly focusing on alleviation of symptoms. Therefore,
numerous OA animal models have been developed aiming at better
understanding the mechanisms, developing new strategies to slow
down the degenerative process, and exploring effective and timely
diagnosis of the disease.
OA models have been induced by many methods in a variety of
animal species78. Among them, genetically-modiﬁed mice offer a
potential to understand the molecular mechanisms of OA initia-
tion and progression. Since OA is thought to be a multifactorial
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SLRP-deﬁcient mice, to best understand OA disease progression.
As various SLRPs single- and double-deﬁcient mice develop OA,
such mutant mice provide important new tools to investigate the
molecular mechanisms underlying this disease. Importantly, the
SLRP-deﬁcient mice model with a wide variety in progression rate
of OA is currently advantageous over any other animal model. For
instance, the BGN/ﬁbromodulin double-deﬁcient mouse presents
an earlier and faster progression of OA, making it a model of
choice for rapid advances in OA research. On the contrary, a more
slowly evolving OA with comparable etiology can be investigated
in the BGN or ﬁbromodulin single-deﬁcient mouse. Indeed, many
ﬁndings from these SLRP-depleted mouse models have shed light
on how SLRPs inﬂuence the molecular events that lead to OA53.
TGF-b interacts with a number of cartilage ECM proteins. The
functional link between ECM proteins, TGF-b activity and OA has
been indicated by a number of studies on SLRPs34,63. This suggests
that agents controlling and modifying the TGF-beECM system are
promising targets for treatment, thus offering a new therapeutic
strategy for OA. The dichotomy of TGF-b effects is noteworthy in
different joint tissues. While its induction of a chondrogenic
response can be viewed as cartilage reparative, TGF-b can also
trigger problems in other tissues of the joint and results in
ﬁbrosis and osteophyte formation60. SLRPs may function to
regulate the beneﬁcial vs harmful effects of TGF-b signals63. It is
therefore of great interest to understand how SLRPs might
modulate these aspects of TGF-b induction, and which SLRPs
might be most important in repair of chondroid or ﬁbrogenic
tissues, before an SLRP-targeted therapeutic modality can be
anticipated.
As aforementioned, the majority of current ﬁndings came from
SLRP-deﬁcient mice models regarding the involvement of SLRPs in
the pathogenesis of OA. However, little is known about the possible
role of SLRPs in validatedmurine OA-likemodels. It should be noted
that themolecular mechanisms of both joint structural damage and
pain may be distinct in animal models of OA induced or initiated by
different means78. Obviously, an important distinction exists be-
tween murine SLRPs deﬁciencies and murine OA-like models (with
a single precipitating event such as joint injury) since the SLRP
deﬁciencies described are conventional KOs and therefore the pa-
thology is bound to be inﬂuenced by developmental and growth
abnormalities. Humans with such abnormalities represent a very
minor group of the OA population. As such, more investigations
using multiple OA animal models are necessary to enrich our un-
derstandings in this aspect. However, subsequent interpretation of
the data and its extrapolation to the human condition must be
more precise78.
At present, diagnosis of OA can be made by imaging tech-
niques only after irreversible damage to the joint occurs. As
cartilage has a limited capacity to regenerate, it should be bene-
ﬁcial to detect and treat OA at an earlier stage. A variety of OA-
associated protein fragments have been reported as possible
biomarkers to evaluate cartilage metabolism or OA progression,
including some SLRPs fragments35e37,79,80. Monfort et al.59
demonstrated the ability of human recombinant MMP-13 to
cleave BGN and ﬁbromodulin extensively, and characterized a
novel major cleavage site for BGN. The susceptibility of cartilage
SLRPs catabolites during cartilage destruction was further high-
lighted by Young and colleagues81, who advocated a strategy of
monitoring SLRP fragmentation as a promising biomarker strat-
egy to evaluate OA status. It will be of substantial interest to
ascertain whether OA-associated alterations in usurped SLRP
fragments correlate with disease severity, and to ultimately
detect some SLRP core protein fragments as valuable biomarkers
for joint disease initiation and development.Author contributions
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